Acura Pharmaceuticals, Inc. (ACUR)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acura Pharmaceuticals, Inc. (ACUR) trades at $0.00 with AI Score 48/100 (Grade C). Acura Pharmaceuticals, Inc. focuses on developing and commercializing technologies to improve medication safety. Market cap: $59,402, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for ACUR: ACUR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACUR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ACUR: the 1 perspectives are evenly split.
How is this calculated? →Acura Pharmaceuticals, Inc. (ACUR) Healthcare & Pipeline Overview
Acura Pharmaceuticals, Inc. is a drug delivery company focused on developing and commercializing technologies for safer medication use, particularly in pain management and nasal decongestion. Its product portfolio includes Oxaydo and Nexafed, with ongoing research into abuse-deterrent formulations and collaborative agreements for global market expansion.
What Is the Investment Thesis for ACUR?
Acura Pharmaceuticals, Inc. presents a focused investment opportunity within the specialty pharmaceutical sector. The company's commitment to developing abuse-deterrent formulations addresses a critical need in pain management. Key value drivers include the potential for increased adoption of Oxaydo and Nexafed products, coupled with successful development and commercialization of its pipeline products, including LTX-03. The company's gross margin of 94.2% indicates strong pricing power. However, the company's negative profit margin of -56.2% and negative free cash flow of $-0.00B highlight the need for improved financial performance. Upcoming catalysts include potential regulatory approvals for new formulations and expansion of existing product lines. Potential risks include competition from established pharmaceutical companies and challenges in securing additional funding for research and development.
Based on FMP financials and quantitative analysis
ACUR Key Highlights
- Gross Margin of 94.2% indicates strong pricing power in its product offerings.
- Negative Profit Margin of -56.2% reflects ongoing investments in research and development and commercialization efforts.
- Free Cash Flow of $-0.00B indicates the company is currently reliant on external funding.
- Beta of -54.49 suggests the stock price is inversely correlated with the market.
- The company has six additional opioid products in various stages of formulation development, signaling future growth potential.
Who Are ACUR's Competitors?
ACUR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACUR's Key Strengths?
- Proprietary abuse-deterrent drug delivery technologies.
- Established partnerships with other pharmaceutical companies.
- Focus on a growing market segment (abuse-deterrent formulations).
- High gross margin (94.2%).
What Are ACUR's Weaknesses?
- Negative profit margin (-56.2%).
- Negative free cash flow.
- Small number of employees (9).
- Limited product portfolio.
What Could Drive ACUR Stock Higher?
- Potential regulatory approval for new abuse-deterrent formulations.
- Expansion of existing product lines into new markets.
- Research and development of new drug delivery technologies.
- Strategic partnerships with other pharmaceutical companies.
- Efforts to increase market share for Oxaydo and Nexafed.
What Are the Key Risks for ACUR?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory changes impacting opioid prescriptions and abuse-deterrent formulations.
- Challenges in securing funding for research and development.
- Dependence on key partnerships for product development and commercialization.
- Limited liquidity due to trading on the OTC market.
What Are the Growth Opportunities for ACUR?
- Expansion of Oxaydo Market Share: Acura has the opportunity to increase the market share of Oxaydo, its abuse-deterrent opioid, by targeting specific patient populations and expanding its distribution network. The market for abuse-deterrent opioids is growing due to increasing awareness of opioid abuse and regulatory initiatives promoting safer pain management options. Success in this area could significantly boost revenue within the next 2-3 years.
- Commercialization of LTX-03: The successful development and commercialization of LTX-03, an immediate-release tablet utilizing LIMITx technology, represents a significant growth opportunity for Acura. This product aims to provide effective pain relief while minimizing the risk of abuse. Positive clinical trial results and regulatory approval could lead to substantial revenue generation within the next 3-5 years.
- Geographic Expansion: Acura can explore opportunities to expand its geographic reach by partnering with international distributors or establishing a direct presence in key markets. The global market for pain management and nasal decongestant products is substantial, and expanding into new regions could drive significant revenue growth over the next 5 years.
- Development of New Abuse-Deterrent Formulations: Acura's expertise in drug delivery technology positions it to develop new abuse-deterrent formulations for other commonly abused medications. This could involve partnering with other pharmaceutical companies or developing its own proprietary products. Successful development and commercialization of new formulations could create new revenue streams within the next 3-5 years.
- Strategic Partnerships and Acquisitions: Acura can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. This could involve acquiring companies with complementary technologies or products, or partnering with larger pharmaceutical companies to co-develop and commercialize new medications. Such partnerships could accelerate growth and diversify revenue streams over the next 2-5 years.
What Opportunities Does ACUR Have?
- Expansion of Oxaydo market share.
- Commercialization of LTX-03.
- Geographic expansion.
- Development of new abuse-deterrent formulations.
What Threats Does ACUR Face?
- Competition from larger pharmaceutical companies.
- Regulatory changes impacting opioid prescriptions.
- Challenges in securing funding for research and development.
- Potential product liability claims.
What Are ACUR's Competitive Advantages?
- Proprietary drug delivery technologies that enhance medication safety.
- Patents protecting its formulations and technologies.
- Established partnerships with other pharmaceutical companies.
- Expertise in developing abuse-deterrent formulations.
What Does ACUR Do?
Acura Pharmaceuticals, Inc., established in 1935 and headquartered in Palatine, Illinois, is dedicated to the research, development, and commercialization of pharmaceutical products designed to improve medication safety. The company's primary focus is on creating innovative drug delivery technologies that address the challenges associated with prescription drug abuse and misuse. Acura's product portfolio includes Oxaydo, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain. Additionally, the company offers Nexafed products, which are pseudoephedrine and acetaminophen tablets used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy medications. Acura Pharmaceuticals operates through strategic collaboration and license agreements with companies like Egalet US, Inc., Egalet Ltd., and Abuse Deterrent Pharma, LLC. These partnerships enable Acura to manufacture, commercialize, and further develop its product offerings, including LTX-03, an immediate-release tablet utilizing LIMITx technology. With a lean team of 9 employees, Acura Pharmaceuticals continues to innovate in the drug delivery space, aiming to provide safer and more effective medication options.
What Products and Services Does ACUR Offer?
- Develops and commercializes pharmaceutical products.
- Focuses on abuse-deterrent drug delivery technologies.
- Offers Oxaydo tablets for pain management.
- Provides Nexafed products for nasal decongestion.
- Engages in research and development of new formulations.
- Collaborates with other pharmaceutical companies for product development and commercialization.
How Does ACUR Make Money?
- Develops and patents proprietary drug delivery technologies.
- Manufactures and sells pharmaceutical products through partnerships and direct sales.
- Generates revenue through product sales and licensing agreements.
- Invests in research and development to expand its product pipeline.
What Industry Does ACUR Operate In?
Acura Pharmaceuticals, Inc. operates within the specialty pharmaceutical industry, which is characterized by a focus on developing niche products and innovative drug delivery systems. The industry is driven by the need for safer and more effective medications, particularly in areas such as pain management and abuse deterrence. The competitive landscape includes both large pharmaceutical companies and smaller, specialized firms. Acura's focus on abuse-deterrent formulations positions it within a growing segment of the market, driven by increasing concerns about opioid abuse and regulatory pressures to develop safer alternatives. The global pharmaceutical market is projected to reach trillions of dollars by 2026, with specialty pharmaceuticals representing a significant portion of this growth.
Who Are ACUR's Key Customers?
- Patients suffering from acute and chronic pain.
- Individuals seeking relief from nasal congestion.
- Pharmaceutical companies seeking to incorporate abuse-deterrent technologies into their products.
- Distributors and wholesalers of pharmaceutical products.
Net buyingInsider Activity
The most recent 12 insider filings for Acura Pharmaceuticals, Inc. break down as 4 sales and 8 purchases. On net that is roughly 200K shares acquired (about $2K) — insiders putting money in tends to read as conviction.
ACUR Valuation & Market Position
With a 59K market cap, Acura Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ACUR's quantitative score of 48/100 is below the peer average of 66/100.
ROE 31%Key Financial Metrics
Return on equity for Acura Pharmaceuticals, Inc. stands at 30.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.72 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Acura Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Acura Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Palatine, US. The company is led by CEO Robert Jones. ACUR has traded publicly since 1986.
ACUR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that insiders believe in the potential for growth.
- Community sentiment has shifted positively with recent announcements about drug development progress, boosting investor optimism.
- Increased media coverage around their innovative pain management solutions has raised awareness and interest in the stock.
- The overall market trend towards pharmaceutical innovations has created a favorable environment for companies like Acura Pharmaceuticals.
Bear Case
- Concerns over the regulatory hurdles for their drug candidates have created uncertainty among investors, leading to skepticism about future approvals.
- Recent discussions in trading forums reveal a cautious sentiment, with many investors worried about the company's cash flow situation.
- Market perception remains clouded by past performance issues, causing some traders to question the sustainability of any recent gains.
- The stock has faced bearish sentiment due to broader market volatility, which often impacts smaller pharmaceutical companies disproportionately.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ACUR Latest News
No recent news available for ACUR.
ACUR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACUR.
Price Targets
Wall Street price target analysis for ACUR.
ACUR MoonshotScore
What does this score mean?
The MoonshotScore rates ACUR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Robert Jones
CEO
Robert Jones serves as the CEO of Acura Pharmaceuticals, Inc., leading a team of 9 employees. Information regarding his detailed career history, education, and previous roles is not available in the provided source data. Therefore, a comprehensive background summary cannot be provided at this time.
Track Record: Due to the limited information available in the provided source data, a detailed track record of Robert Jones' key achievements, strategic decisions, and company milestones under his leadership cannot be accurately assessed.
ACUR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acura Pharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity, price volatility, and lack of transparency compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to low trading volume on the OTC market.
- Higher price volatility compared to exchange-listed stocks.
- Potential for limited or inconsistent financial disclosures.
- Increased risk of fraud or manipulation due to less regulatory oversight.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the company's capital structure and debt levels.
- Determine the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been incorporated since 1935, indicating a long operating history.
- Acura Pharmaceuticals, Inc. has existing commercialized products (Oxaydo and Nexafed).
- The company has collaboration and license agreements with other pharmaceutical companies.
- Acura Pharmaceuticals, Inc. is focused on developing abuse-deterrent formulations, addressing a significant public health concern.
- The company has a team of employees, suggesting ongoing operations.
What Investors Ask About Acura Pharmaceuticals, Inc. (ACUR) — Healthcare
What does Acura Pharmaceuticals, Inc. do?
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products with abuse-deterrent properties. Their portfolio includes Oxaydo, an immediate-release oxycodone tablet formulated to deter abuse, and Nexafed, a pseudoephedrine tablet designed to resist methamphetamine production. The company leverages its proprietary Aversion and Impede technologies to create safer versions of commonly abused medications, addressing the critical need for abuse-deterrent options in pain management and other therapeutic areas. Acura operates through strategic partnerships and internal research and development efforts.
What are the main risks for ACUR?
Acura Pharmaceuticals, Inc. faces several risks inherent to the pharmaceutical industry and its specific business model. Competition from larger pharmaceutical companies with greater resources poses a significant threat. Regulatory changes impacting opioid prescriptions and abuse-deterrent formulations could also negatively affect the company's prospects. Securing funding for research and development is crucial for Acura's long-term success, and any challenges in this area could hinder its growth. Furthermore, the company's reliance on key partnerships exposes it to risks associated with the performance and strategic decisions of its collaborators.
What revenue streams does Acura Pharmaceuticals, Inc. have in healthcare?
Acura Pharmaceuticals, Inc. generates revenue primarily through the sale of its pharmaceutical products, Oxaydo and Nexafed. Oxaydo, an abuse-deterrent opioid, contributes to revenue through prescriptions for pain management. Nexafed, a nasal decongestant, generates revenue through over-the-counter and prescription sales. Additionally, Acura may receive revenue from licensing agreements and partnerships related to its proprietary drug delivery technologies. The company's revenue streams are concentrated in the United States, with potential for future expansion into international markets through strategic partnerships.
How does Acura Pharmaceuticals, Inc. address the opioid crisis?
Acura Pharmaceuticals, Inc. addresses the opioid crisis by developing and commercializing abuse-deterrent formulations of opioid medications. Its Oxaydo tablets are designed to be more difficult to crush, snort, or inject, reducing the potential for misuse and abuse. By providing safer alternatives to traditional opioid painkillers, Acura aims to contribute to the reduction of opioid-related addiction and overdose. The company's focus on abuse-deterrent technology aligns with regulatory efforts to combat the opioid crisis and promote responsible pain management practices.
What are the key factors to evaluate for ACUR?
Acura Pharmaceuticals, Inc. (ACUR) holds an AI score of 48/100 (low). Not financial advice.
How frequently does ACUR data refresh on this page?
ACUR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ACUR's recent stock price performance?
Acura Pharmaceuticals, Inc. (ACUR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary abuse-deterrent drug delivery technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACUR overvalued or undervalued right now?
Valuing Acura Pharmaceuticals, Inc. (ACUR) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights in the future.